Navigation Links
MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
Date:12/13/2007

Results to be presented at San Antonio Breast Cancer Symposium

AMSTERDAM, Netherlands, Dec. 13 /PRNewswire/ -- Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced today that an independent international consortium has demonstrated the prognostic power of its MammaPrint(R) breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint(R) can accurately identify a low risk group of lymph node-positive breast cancer patients with an excellent survival, implications that will help doctors to decide the optimal treatment management.

"Lymph node status is considered to be one of the most powerful prognostic factors for operable breast cancer, with a direct relationship between the number of positive nodes and disease outcome. However, approximately 30% of lymph node-positive patients will remain free of distant metastases without adjuvant chemotherapy," said Dr Laura van 't Veer, chief research officer at Agendia, who participated in the study. "Identifying patients with lymph node-positive disease who are at low risk of recurrence might lead to changes in guidelines for adjuvant chemotherapy."

In the current study, 241 tumor samples from breast cancer patients with 1-3 positive lymph nodes at 2 hospitals were selected and analyzed by the international TRANSBIG consortium. Patients that were classified as "high risk" for recurrence using MammaPrint(R) had significantly worse 5- and 10-year survival rates than those that were identified as "low risk." The numbers indicate that MammaPrint(R) has excellent prognostic power, even in patients having 1-3 positive lymph nodes. The entire study will be presented as an oral presentation at the San Antonio Breast Cancer Symposium on Thursday, December 13 in San Antonio, TX, USA.

"This study is in excellent agreement with our 2002 publication in the New England Journal of Medicine in which we also found that MammaPrint(R) is a powerful predictor of disease outcome in lymph node positive breast cancer patients," said Prof. Dr. Rene Bernards, chief scientific officer at Agendia. "Based on these data, the inclusion criteria of the large MINDACT clinical trial using MammaPrint(R) will be enlarged to include patients with 1-3 positive nodes."

Agendia will start offering MammaPrint(R) to patients having 1-3 positive lymph nodes in Europe. These data will also be submitted to the U.S. Food and Drug Administration (FDA) for regulatory approval at a later date.

About MammaPrint(R)

MammaPrint(R) laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint(R) measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint(R) test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint(R) tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to receive FDA approval for its breast cancer test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary." Agendia recently also presented its new colon cancer prognosis test, ColoPrint(R), which is currently undergoing further validation. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
4. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
5. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
6. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
7. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
8. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
11. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Miami (PRWEB) , ... February 11, 2016 , ... ... opening of its new stem cell treatment clinic in Quito, Ecuador. The new ... orthopedic and trauma applications to patients from around the world. , The ...
(Date:2/10/2016)... WASHINGTON , Feb.10, 2016 ASAE is ... and Association Management Companies (AMC) the option of joining ... flat annual fee determined by staff size, every employee ... to join ASAE and reap all available member benefits.   ... CAE. "Our new organizational membership options will allow organizations ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
(Date:2/10/2016)... ... 10, 2016 , ... Curoverse announced today that the open-source, ... capabilities for managing and processing genomic and health data at petabyte scale. ... and analyzing genomic data,” said Adam Berrey chief executive officer at Curoverse. “Microsoft ...
Breaking Biology Technology:
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
(Date:1/11/2016)... 11, 2016  higi, the leading retail and ... locations, web and mobile, today announced it has ... existing investors. --> ... further innovate higi,s health platform – its network ... – including expanding services and programs to retail ...
(Date:1/8/2016)... January 8, 2016 NXTD ), ... WorldVentures ® , a privately held leading direct seller ... Inc. 5000 fastest-growing company announced that on December ... $2 million in Nxt-ID to develop a proprietary new ... Wocket ® , a unique smart wallet that serves ...
Breaking Biology News(10 mins):